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Summary 
Genetic evidence suggests a role for apolipoprotein E 
(apoE) in Alzheimer’s disease (AD) amyloidogenesis. 
Here, amyloid-associated apoE from 32 AD patients 
was purified and characterized. We found that brain 
amyloid-associated apoE apparently exists not as free 
molecules but as complexes with polymers of the amy- 
loid g peptide (Af3). Brain Af%apoE complexes were 
detected irrespective of the apoE genotype, and simi- 
lar complexes could be mimicked in vitro. The fine 
structure of purified A3-apoE complexes was fibrillar, 
and immunogold labeling revealed apoE immunoreac- 
tivity along the fibrils. Thus, we conclude that AP-apoE 
complexes are principal components of AD-associated 
brain amyloid and that the data presented here support 
a role for apoE in the pathogenesis of AD. 
Introduction 
Alzheimer’s disease (AD) is an aging-related dementia 
without known treatments. One invariant neuropathologi- 
cal feature of AD is deposition of intracerebral and menin- 
geal amyloid (reviewed in Selkoe, 1991). The predominant 
component of AD-associated amyloid is the amyloid 6 pep- 
tide (A& which is mainly 40-42 amino acid residues in 
length (Glenner and Wong, 1984; Masters et al., 1985; 
Roher et al., 1993; Naslund et al., 1994). A8 is derived by 
proteolytic processing of an integral membrane protein, 
the j3-amyloid precursor protein (Kang et al., 1987). The 
A8 peptide is detectable in soluble form in plasma and 
cerebrospinal fluid (Seubert et al., 1992) and in medium 
from cell cultures (Haass et al., 1992) whereas in amyloid 
deposits, the A6 peptide forms an insoluble and protease- 
resistant core (Masters et al., 1985). The physicochemical 
properties of A6 enable it to form polymers and fibrils spon- 
taneously (Kirschner et al., 1987; Nordstedt et al., 1994). 
It has, however, been suggested that other proteins pres- 
ent in, or in the vicinity of, the amyloid may act as”patholog- 
ical chaperones,” facilitating A8 fibrillogenesis and depo- 
sition (Wisniewski and Frangione, 1992). A number of 
proteins unrelated to A8 have been detected immunohis- 
tochemically in AD-associated amyloid. These include 
heparan sulfate proteoglycans (Snow et al., 1990), al-anti- 
chymotrypsin (ACT; Abraham et al., 1988), amyloid P com- 
ponent (Coria et al., 1988) complement proteins (Roze- 
muller et al., 1989), and, most notably, apolipoprotein E 
(apoE; Namba et al., 1991; Wisniewski and Frangione, 
1992). 
apoE is a 299 residue protein with a molecular mass of 
approximately 34 kDa. In plasma, apoE associates with 
lipoproteins and mediates transport of lipids and choles- 
terol into the cells by binding to the low density lipoprotein 
receptor or the low density lipoprotein receptor-related 
protein/az-macroglobulin receptor (for review, see Weis- 
graber, 1994). apoE exists in three major isoforms, apoE2, 
apoE and apoE4, which are products of the ~2, ~3, and 
~4 alleles, respectively. The isoforms differ in arginine or 
cysteine content at positions 112 and 158. Recent genetic 
studies suggest a role for apoE in the pathogenesis of AD. 
The frequency of the ~4 allele is significantly higher in 
sporadic (Mayeux et al., 1993; Rebeck et al., 1993; Saun- 
ders et al., 1993) and familial late onset AD (Corder et 
al., 1993; Strittmatter et al., 1993a) than in the general 
population. In addition, brain tissue from AD patients car- 
rying the ~4 allele contains more amyloid than brain tissue 
from AD patients with other apoE genotypes (Rebeck et 
al., 1993; Schmechel et al., 1993; Berr et al., 1994) im- 
plying a direct role for apoE in cerebral amyloidogenesis. 
How apoE might promote accumulation of amyloid and 
development of AD is still not understood. Recent in vitro 
experiments suggest that both apoE and apoE bind A8 
peptide variants in a f3-mercaptoethanol-sensitive manner 
(Strittmatter et al., 1993b; LaDu et al., 1994). The com- 
plexes formed are stable to boiling in SDS, implying strong 
intermolecular binding. Electron microscopic analysis of 
these in vitro complexes demonstrated that both apoE 
and apoE interact with A8 to form monofibrillar struc- 
tures, distinct from the twisted ribbons formed by synthetic 
A8 alone (Sanan et al., 1994). It has also recently been 
shown that apoE (Maet al., 1994; Wisniewski et al., 1994) 
and ACT (Ma et al., 1994) enhance polymerization of A8 
in vitro, thereby providing a direct link between these pos- 
tulated pathological chaperones and amyloid formation. 
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Figure 1. lmmunoblot Analysis of Amyloid-Enriched HFIP Extracts 
from AD Patients and Nondemented Controls 
Amyloid-enriched HFIP extracts from 2 AD patients and 2 nonde- 
mented controls, respectively, were separated by SDS-PAGE, elec- 
troblotted onto nitrocellulose membranes, and probed with A6-specific 
antibody 6ElO or apoE-specific antibody 2El. The total amount of 
protein in each lane was 60 pg. Positions of the molecular mass mark- 
ers in kilodaltons are shown at left. 
Amyloid-associated apoE purified from human brain tis- 
sue has not previously been studied biochemically. We 
have extracted AD-associated amyloid deposits from pa- 
renchymal brain tissue and report here that a C-terminal 
fragment of apoE apparently exists in a complex with A6 
polymers of varying sizes. Considerably more AD-apoE- 
immunoreactive complexes were recovered from AD 
brains than from brains of elderly, nondemented controls. 
The A6-apoE complexes were detectable in brain extracts 
from all 32 AD patients examined, without apparent rela- 
tionship to the apoE genotype (~31~3, .53/~4, or ~41~4). The 
purified AD-apoE complexes were resistant to various 
agents previously shown to dissociate A8 polymers, im- 
plying strong intermolecular association. When viewed by 
negative stain electron microscopy, the AD-apoE com- 
plexes appeared as bundles of tightly packed amyloid fi- 
brils morphologically similar to those of noncomplexed A8 
purified from AD brain. lmmunogold labeling of the purified 
complexes demonstrated that apoE immunoreactivity was 
distributed along the fibrils and fibril bundles. Complexes 
formed in vitro between synthetic A6 and recombinant 
apoE showed chromatographic, immunoreactive, and 
morphological features indistinguishable from the Aj3- 
apoE complexes purified from AD brain. 
Results 
Detection of Highly Insoluble AP-apoE Complexes 
in AD Brain Tissue 
Amyloid-enriched brain tissue fractions from 32 AD pa- 
tients and 4 nondemented controls were extracted with 
hexafluoro-Ppropanol (HFIP). Extracted proteins from 2 
representative patients in each group were analyzed by 
immunoblotting using the A8-specific antibody 6E10 or the 
apoE-specific antibody2El (Figure 1). In the samples from 
the AD patients, but not from the nondemented controls, 
a prominent band with an apparent molecular mass of 
- 4.5 kDa was labeled by antibody 6ElO. This species was 
identified as a mixture of intact and N-terminally truncated 
A8(1-40) and A8(1-42) variants by microsequencing and 
electrospray mass spectrometry (Naslund et al., 1994). In 
addition to small quantities of A8 oligomers, the AD sam- 
ples contained high molecular mass forms of A8 ranging 
in size from 22 to 24 kDa to the separation limit of the gel, 
corresponding to A3 polymers of varying sizes. Immu- 
noblotting of the same extracts using the apoE-specific 
antibody 2El yielded a staining pattern very similar to that 
obtained with 6E10, except that 2El did not label mono- 
meric and oligomeric A6 (Figure 1). Hence, 2El-immune 
reactive material was apparently comigrating with A8 poly- 
mers in SDS-PAGE. The immunoreactivity of both 
antibodies could be abolished by preabsorption with their 
respective antigens. The similar appearances of the AD- 
and apoE-immunoreactive material indicate that the two 
antibodies may have bound to the same structures, i.e., 
SDS-resistant complexes formed by apoE and polymers 
of A6. Hereafter, these structures will be referred to as 
A6-apoE complexes. As seen in Figure 1, the apparent 
mass of the smallest A8-apoE complex is 22-24 kDa, 
which is below the nominal 34 kDa mass of apoE, sug- 
gesting that the apoE component of the complexes is trun- 
cated (see below). 
Purification of the Ap-apoE Complexes from AD 
Brain Tissue 
To enable biochemical and morphological studies of the 
AD-apoE complexes, a protocol for partial purification was 
developed. Proteins from an amyloid-enriched AD brain 
tissue fraction were first separated by gel filtration on a 
Superose 12 column (Figure 2A). Using this method, pro- 
teins smaller than 22 kDa (including monomeric and oligo- 
merit A6 peptide not associated with apoE) were effi- 
ciently separated from the remainder of the material. The 
amount of A8 immunoreactivity apparently residing in 
apoE-complexed form varied, but was densitometrically 
determined to constitute at least 50% of the total A6 immu- 
noreactivity in each case (Figure 28). Fractions containing 
the Aj3-apoE complexes (fractions 2-3) were pooled and 
then subjected to reverse-phase liquid chromatography 
(RPLC; Figure 2C). Previous experiments had shown that 
noncomplexed A6 elutes at - 18% acetonitrile (ACN) in 
this RPLC system (data not shown). The Af3-apoE com- 
plexes eluted as a broad peak between 24% and 29% 
ACN (Figure 2D). It is noteworthy that all fractions con- 
taining A8 polymers also displayed apoE immunoreactiv- 
ity. Fractions 7-l 0 from the RPLC sessions were pooled 
and used in the subsequent characterization and dissocia- 
tion experiments. 
Immunological and Biochemical Characterization 
of the Afl-apoE Complexes 
A set of different antibodies was used to investigate 
whether the A6-apoE complexes harbored molecules 
other than A6 and apoE and to rule out cross-reaction 
between antibodies. As seen in Table 1, the only antibod- 
ies labeling the complexes were those raised against A8 or 
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Figure 2. Fractionation of an Amyloid-Enriched HFIP Extract by Gel 
Filtration on a Superose 12 Column 
(A) Absorbance profile at 280 nm of the HFIP extract eluted in 70% 
formic acid. Fractionation started after an elution volume of 6 ml. Mono- 
meric, noncomplexed A6 eluted at - 13.5 ml (fraction 9) in this system. 
(6) lmmunoblot analysisof the Superose 12fractions. Aliquots of each 
fraction were separated by SDS-PAGE, electroblotted onto nitrocellu- 
lose membranes, and probed with Af3-specific antibody 6ElO (closed 
circles) or apoE-specific antibody 2El (open circles). The resulting 
autoradiograms were quantified by densitometry. Scanning was per- 
formed over the full length of each lane, and therefore optical density 
values refer to the total immunoreactivity in each sample. 
(C) AB-apoE complexes recovered from the Superose 12 column were 
further purified by RPLC on a Vydac C4 column and developed with 
a linear gradient of buffer B (see Experimental Procedures for details). 
(D) Each RPLC fraction was probed with AD-specific antibody 6E10 
(closed circles) or apoE-specific antibody 2El (open circles) and sub- 
jected to the same analysis as in (E). 
apoE. Interestingly, antibody 1 D7, recognizing an epitope 
overlapping the LDL receptor-binding domain located be- 
tween residues 142-158 of apoE, did not label the com- 
plexes. In control immunoblot experiments, 1 D7 intensely 
labeled recombinant apoE. This, together with the positive 
labeling obtained with antibody 3Hl (recognizing an epi- 
Table 1. lmmunoreactivity of the AD-apoE Complexes As 
Determined by lmmunoblotting 
Antibody Specificity Reactivity 
.- 
MAB 6ElO AP + 
MAb 4G6 AP fa 
G504 AD +a 
Anti-A6 AP +a 
MAb 2El apoE + 
MAb 1048 apoE +b 
MAb 3Hl apoE i” 
MAb lD7 apoE 
MAb 22Cll APP 
MAb Al290 APP 
369A APP - 
MAb 56-1 APP (KPI) 
Anti-ACT ACT 
Anti-ubiquitin ubiquitin 
Anti-TTR l-m 
MAb tau-1 tau 
MAb AT-8 P-tau 
a Similar staining as with 6ElO. 
’ Similar staining as with 2El. 
ACT, rkantichymotrypsin; APP, 6-amyloid precursor protein; KPI, 
Kunitz protease inhibitor; P-tau, phosphorylated tau; TTFI, transthyretin. 
tope between residues 220-272) suggests that the Af3- 
apoE complexes are composed of the C-terminal part of 
apoE. Although material reactive with antibodies to the 
f3-amyloid precursor protein, ACT, ubiquitin, and phos- 
phorylated tau could be recovered from AD brain using 
the same extraction protocol, none was associated (i.e., 
copurified) with the AD-apoE complexes. 
Microsequencing confirmed that A6 was a component 
of the complexes. A Lys-C digest contained two peptides 
with A6 sequences, one in the 0.1% trifluoroacetic acid 
(TFA)-soluble fraction and one in the formic acid-soluble 
fraction (see Experimental Procedures). The sequence ob- 
tained in the 0.1% TFA-soluble fraction was XXIIGLMV 
(eluting at 32% ACN), corresponding to residues 29-36 
of Af3. In the formic acid-soluble fraction, the sequence 
XAEFRHDSGYEVH (eluting at 35% ACN), corresponding 
to residues l-l 3 of A6, was obtained. We were unable to 
obtain any sequence corresponding to apoE, either by 
trypsin or by Lys-C digestion. This was interpreted as evi- 
dence either that apoE was present in levels too low to 
allow microsequencing or that the apoE moiety of the com- 
plex adopts a conformation too dense to allow penetration 
of the proteases used. 
Association of Ap-apoE Complexes by Strong 
Intermolecular Bonds 
It was hypothesized that the A6 and apoE components in 
the complexes might be separated if the material were 
exposed to strong dissociating agents. The A@apoE com- 
plexes were therefore treated with acids, bases, deter- 
gents, chaotropic or denaturing agents, or organic sol- 
vents (see Experimental Procedures), some of which have 
previously been shown to dissociate A6 polymers purified 
from AD brain (Masters et al., 1985). The incubates were 
separated by SDS-PAGE, electroblotted onto nitrocellu- 
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Figure 3. Congo Red-Stained AP-apoE Complexes Demonstrate 
Green Eirefringence When Viewed under Polarized Light 
Purified AD-apoE complexes were suspended in 50% ethanol con- 
taining 1% Congo red, smeared onto glass slides, and viewed under 
polarized light at a magnification of 200 x 
lose membranes, and analyzed with antibody 6ElO. The 
criteria used when determining whether the complexes 
had dissociated were reduced amounts of AD-apoE com- 
plex immunoreactivity with a molecular mass higher than 
22-24 kDa and appearance of detectable amounts of A6 
immunoreactivity within the 3-5 kDa region. Either crite- 
rion would indicate that the A6 peptide had been released 
from the complexes. None of the agents employed in- 
duced any measurable dissociation. 
AJI-apoE Complex Formation and apoE lsoforms 
Af3-apoE complexes were detected in brain extracts from 
all 32 AD patients studied. In 21 of the patients, the apoE 
genotype was known, showing the following distribution: 
Es/E3 (n = 8) Es/Ed (n = 12), and E4/E4 (fl = 1). No AD 
patient with an ~2 allele was present in this study, probably 
owing to the reported low frequency of this allele among 
AD patients (4.4%; Peacock and Fink, 1994). 
Morphological Examination of Afi-apoE Complexes 
and Noncomplexed AP 
The tinctorial properties of the purified Af3-apoE com- 
Figure 4. Negative Stain Electron Microscopy of Aggregated AB- 
apoE Complexes and Noncomplexed Af3 
(A) The purified AD-apoE complexes were incubated in TBS for 1 hr, 
negativelystained with2% uranyl acetate, andexaminedinanelectron 
microscope. 
(6) Less dense fibril matrix found in another region of the same speci- 
men as in (A). 
(C) Noncomplexed A!3 purified from AD brain tissue incubated and 
stained as in (A). 
Bars, 100 nm. 
plexes were indistinguishable from those typical of tissue 
amyloid (Glenner, 1980); i.e., when stained with Congo 
red, they manifested green birefringence under polarized 
light (Figure 3). The fine structure of the Af3-apoE com- 
plexes was investigated further by electron microscopy. 
After negative staining with uranyl acetate, tight bundles 
of fibrils were found (Figure 4A). The strictly parallel ar- 
rangement of the fibrils resembles that previously ob- 
served in AD brain tissue (Davies and Mann, 1993). In 
some regions, the bundles had apparently separated, and 
finer substructures became evident (Figure 48). Thus, a 
web-like matrix could be seen, which in its finest exten- 
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Figure 5. lmmunogold Labeling of the Ab-apoE Complexes 
(A) Labeling of Ab-apoE complexes with antibody against apoE (2El), 
followed by negative staining. 
(B) Labeling of the same specimen as in (A) with normal mouse IgG 
as a control for nonspecrfic binding of the primary antibody. 
Bars, 100 nm. 
sions consisted of one or a few fibrils twisted around each 
other. The fibrils had a diameter of 6-8 nm, in good accor- 
dance with published data on the dimensions of A8 fibrils 
(Sanan et al., 1994). The fine structure of noncomplexed 
A8 purified from AD brain (see Figure 2A, fraction 9) is 
shown in Figure 4C. As seen: the general morphology of 
noncomplexed A8 was very similar to that of the Af3-apoE 
complexes. Hence, the morphology of A8 fibrils is similar 
in the presence or absence of apoE. 
lmmunogold labeling of the A6-apoE complexes with 
antibody 2El revealed that both the large fibril bundles 
and the dispersed fibrils were strongly immunoreactive 
(Figure 5A). This suggests that apoE was present not only 
on the surface of the bundles but also between the individ- 
Figure 6. lmmunoblot Analysis of AD-apoE Complexes Formed In 
Vitro 
lmmunoblot analysis of coincubates between Ab and apoE and corre- 
sponding controls. Incubations were performed for 4 days at 37% 
either with (B) or without (A) 10 mM DTT. The products were collected 
by centrifugation and treated with HFIP and 9 M  urea before electro- 
phoresis. Positions of the molecular mass markers in kilodaltons are 
shown at left. 
ual fibrils. Some scattered gold particles could also be 
seen in close proximity to the fibril bundles. These particles 
probably represent labeling of material disrupted from the 
original structures during sonication, since the overall 
background labeling was very low (Figure 5B). 
Reconstitution of Afl-apoE Complexes In Vitro 
To establish further that the Af3-apoE complexes are dis- 
tinct chemical entities and not artifacts attributable to the 
extraction or purification procedures, the formation of Af3- 
apoE complexes was also characterized in vitro. Recombi- 
nant apoE and synthetic Af3( l-40) or A/3( 1-42) were coin- 
cubated under the conditions described in Experimental 
Procedures. Without addition of reducing agents to the 
incubation medium, apoE and apoE interacted with both 
A6 variants and formed heterologous complexes with a 
molecular mass of -40 kDa (Figure 6A). In agreement 
with previous reports, the complexes were SDS-stable 
(Strittmatter et al., 1993b; LaDu et al., 1994) and, in addi- 
tion, were resistant to the HFIP and 9 M urea used in the 
present protocol. It was further evident that only a fraction 
of the total apoE reacted with A6 to form these avid com- 
plexes (varying between 5% and 20010, as determined by 
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Figure 7. Electron Micrographs of At%-apoE Complexes and High Mo- 
lecular Mass Ab Aggregates Generated In Vitro 
(A) Ab-apoE complexes generated in vitro by coincubation of Ab(i- 
40) and apoE in the presence of 10 mM DTT. The complexes were 
purified by gel filtration, polymerized in TBS for 1 hr, and negatively 
stained. 
(B) lmmunogold labeling with 2El of the same specimen as in (A), 
followed by negative staining. 
(C) High molecular mass aggregates of Ab(l-40) that were treated as 
the sample in (A). 
Bars, 100 nm. 
densitometry). If, however, the incubation was performed 
in the presence of a reducing agent (10 mM dithiothreitol 
[OTT]), the complex formation proceeded beyond the stoi- 
chiometric 1 :l complex, and higher molecular mass com- 
plexes labeled with both 6ElO and 2El were formed (Fig- 
ure 6B). In the case of A6(1-40), it is interesting to note 
the stepwise 4 kDa mass increments of the complexes, 
suggesting the successive incorporation of A6 monomers. 
The A@apoE complex bands became less distinct and 
more similar to the in vivo material when using synthetic 
A6(1-42) indicating that the higher hydrophobicity of the 
bound A8 induced aberrant, smear-like migration of the 
complexes in SDS-PAGE. No AB-apoE complexes were 
detected at zero-time incubations (data not shown), con- 
firming that the complexes formed are not artifacts caused 
by postincubation sample treatment. 
The AD-apoE complexes formed under reducing condi- 
tions in vitro were separated from residual noncomplexed 
apoE and A6 by gel filtration in 70% formic acid and exam- 
ined by electron microscopy after negative staining and 
immunogold labeling. As for the A6-apoE complexes 
found in vivo, the high molecular mass products from the 
in vitro coincubations principally formed dense aggregates 
of parallel fibrils. However,  in certain regions, a lattice of 
fibrils with extensive crossover characteristics could be 
found (Figure 7A). In addition, immunogold labeling of the 
in vitro coincubates using anti-apoE antibody demon- 
strated the same pattern of gold particle decoration, albeit 
at a lower density, as that observed for the Af3-apoE com- 
plexes formed in vivo (Figure 78). The lower density of 
immunogold labeling of the in vitro Af3-apoE complexes 
might be an effect of the limited time of incubation, or it may 
bethatefficient, invivo-likecomplexformation requiresan 
additional, unknown factor. Differences in A6 fibril mor- 
phology attributable to either apoE isoform were not ob- 
served. When A8(1-40) or Af3(1-42) was incubated alone, 
both peptides formed high molecular mass products that, 
when subjected to negative staining, displayed the same 
kind of fibril bundles as the in vivo and in vitro AP-apoE 
complexes (Figure 7C). These fibrils were not immunore- 
active to the apoE-specific antibody 2El. Thus, the influ- 
ence of apoE on the final pattern of A6 fibril morphology 
under these experimental conditions seems to be negli- 
gible. 
Discussion 
Here we present evidence that complexes between A8 
and apoE are components of AD amyloid. The complex 
formation occurs with either the apoE or the apoE iso- 
form, as determined by apoE genotype analyses of the 
AD patients and by in vitro reconstitution studies. The A8- 
apoE complexes are joined by uncommonly strong inter- 
molecular bonds, since they were resistant to treatment 
with a number of potent dissociating agents, some of 
which have previously been shown to dissociate A6 poly- 
mers from AD brain (Masters et al., 1985). lmmunoblot 
analysis suggests that the complexes are composed of 
the C-terminal part of apoE, a finding supported by recent 
in vivo studies (Wisniewski et al., 1995) and in vitro binding 
studies (Strittmatter et al., 1993b). The relatively broad 
retention profile of the Af3-apoE complexes in the RPLC 
system used is probably attributable to heterogeneity of 
the complexes, with the smallest complexes being com- 
posed of one apoE and one A6 molecule and the large 
complexes of severalfold more A6 than apoE molecules. 
The molar excess of A6 may also explain why micro- 
sequencing of the complexes yielded A8 fragments but 
no apoE fragments. The retention times of the Af3-apoE 
complexes were consistently longer compared with that 
of noncomplexed A(3 purified from AD brain tissue. These 
longer retention times indicate that the Af3-apoE com- 
plexes are more aggregable than A8 alone. Furthermore, 
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all A3 eluting as polymers in the present chromatography 
system is associated with apoE, suggesting the coexis- 
tence of two populations of A6 in AD amyloid: one that 
is dissociable in HFIP and formic acid and another, the 
apoE-bound, that is resistant to dissociation. This conclu- 
sion is in part supported by immunohistochemical data, 
where antibodies against apoE stain some, but not all, 
Af3-immunoreactive deposits (Strittmatter et al., 1993a; 
Kida et al., 1994). 
It has been suggested that pathological chaperones 
may mediate amyloid formation of polypeptide fragments 
(Wisniewski and Frangione, 1992). The Af3-apoE interac- 
tion described here isof such apparent avidity that dissoci- 
ation of the components under physiological conditions is 
unlikely. The presence of apoE within or at the surface of 
the A/3 fibrils is therefore not surprising. However,  another 
candidate pathological chaperone protein, ACT(Ma et al., 
1994) which by immunohistochemistry has been shown 
to colocalize with Af3 in AD amyloid (Abraham et al., 1988), 
was apparently not bound to A[3 using the present extrac- 
tion and purification protocol. This may reflect a more tran- 
sient mode of ACT interaction with AD. 
The fine structure of the aggregated Af3-apoE com- 
plexes was similar to that of noncomplexed AD, as deter- 
mined by negative stain electron microscopy. The similar 
morphology suggests that the A(3 components of the in 
vivo complexes might be composed primarily of Af3 vari- 
ants ending at residue 42, since At3 variants ending at 
residue 42 are principal components of AD-associated am- 
yloid (Roher et al., 1993; Naslund et al., 1994) and since 
coincubations between Af3(1-42) and apoE in vitro yielded 
a product with an immunoblot appearance nearly identical 
to that of the complexes recovered from AD brain. The 
in vitro-generated, high molecular mass polymers of Ab 
showed the same pattern of tightly aligned fibrils, irrespec- 
tive of the presence or absence of apoE. These results, 
and other recent findings of Lansbury and coworkers (Ev- 
ans et al., 1995), are indicative of a minor role for apoE in 
determining the morphology of A6 fibrils and fibril bundles. 
Rather than influencing the fibril morphology per se, apoE 
may affect the rate of Af3 fibril formation, as in vitro data 
suggest (Ma et al., 1994; Sanan et al., 1994; Wisniewski 
et al., 1994; S. E. G., unpublished data). 
It is particularly interesting that we have detected highly 
stable Af3-apoE complexes in light of the genetic evidence 
that apoE isoforms are an important determinant of an 
individual’s risk for AD. In our study, we observe that these 
complexes can include either apoE or apoE isoforms. 
Moreover, the apoE part of the AB-apoE complexes ap- 
pears to be composed of a C-terminal fragment truncated 
at a site C-terminal to residue 158. This complexed apoE 
fragment is therefore identical in primary structure in all 
three apoE isoforms. A direct interaction between Ab and 
the polymorphic sites in apoE may not be critical, since 
amino acid substitutions at residue 112, the single site at 
which apoE and apoE differ, have been shown to affect 
the structural properties of the C-terminal domain of apoE 
(Dong et al., 1994). The Af3-binding capacity of apoE may 
therefore be governed by domain interactions, similar to 
what has previously been shown to determine the isoform- 
specific lipoprotein preferences of apoE and apoE 
(Dong et al., 1994). It is not clear, though, whether cleav- 
age of apoE occurs before or after A3 binding. 
Since the extraction yield of the AD-apoE complexes is 
not known, and possibly fluctuates between preparations, 
no quantitative interindividual comparison in the amount 
of the complexes was made. However,  examination of the 
immunoblot data from the 32 AD patients does not indicate 
that there was a correlation between the apoE genotype 
and the amount of Af3-apoE complexes extracted. It will 
now be important to determine whether quantitative differ- 
ences can be observed when different isoforms are com- 
pared, orwhether apoE isoforms have adifferential affinity 
for associating secondarily with deposited Af3. Of possible 
relevance to this issue, differential association with soluble 
Ab has been observed for denatured, delipidated apoE 
isoforms (Strittmatter et al., 1993b; Ma et al., 1994; Sanan 
et al., 1994; Wisniewski et al., 1994) and physiological 
apoE isoforms (LaDu et al., 1994). Such differences be- 
tween apoE isoforms in their association with A9 may lead 
to differential proficiency in catalyzing fibril formation (Ma 
et al., 1994; Sanan et al., 1994; Wisniewski et al., 1994) 
thus possibly accounting for the overrepresentation of the 
apoE isoform seen in both sporadic (Mayeux et al., 1993; 
Saunders et al., 1993) and familial AD (Corder et al., 1993; 
Strittmatter et al., 1993a). Alternatively, the isoforms could 
differ in their ability to stabilize the 6 structure of A6 in 
amyloid, since the deposition of Af3 in amyloid has been 
shown to be a dynamic, reversible process (Maggio et al., 
1992). 
The effect of inclusion of DlT in order to obtain in vitro 
A&apoE complexes with similar chromatographic and im- 
munoreactive characteristics as the complexes formed in 
vivo superficially contradicts the results reported by Stritt- 
matter and colleagues, who observed that inclusion of re- 
ducing agents abolished AD-apoE complex formation 
(Strittmatter et al., 1993b; Sanan et al., 1994). The discrep- 
ancy in results is most likely explained by differences in 
the protocols used for complex solubilization prior to SDS- 
PAGE. Since A6 and apoE lack cysteine residues, the 
DTT effect seen in the in vitro coincubates cannot be ac- 
counted for by keeping sulfhydryl groups in a reduced 
state. DlT may instead inhibit the formation of methionine 
sulfoxides and so enhance the ability of apoE to bind oligo- 
mers and polymers of A(3. 
Complex formation between Ab and apoE in vivo might 
have functional consequences related to the ability of 
apoE to bind glycosaminoglycans. ApoE contains two dis- 
tinct heparin-binding sites, one of which is located in the 
C-terminal part of apoE between residues 202 and 243 
(Cardin et al., 1966). This site does not overlap the postu- 
lated AD-binding site in apoE, located between residues 
244 and 272 (Strittmatter et al., 1993b). The apoE moiety 
of the AD-apoE complexes may therefore provide an “an- 
chor”forA(3 polymers, binding them to the glycosaminogly- 
can-rich extracellular matrix of the brain tissue. These an- 
chored Ab polymers can in turn serve as nuclei for further 
A(1 polymerization and growth of amyloid deposits (Jarret 
and Lansbury, 1993). 
Since the AD-apoE complexes were found in significant 
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levels in all 32 AD brains examined and virtually identical 
results were obtained when analyzing amyloid derived 
from leptomeningeal AD tissue (J. N., unpublished data), 
it is proposed that the formation of AD-apoE complexes 
is an invariable feature of AD amyloidogenesis. These in 
vivo observations may be relevant to an elucidation of the 
molecular events that underlie the pathophysiology of ce- 
rebral amyloidogenesis and to improving our understand- 
ing of the role of apoE in this process. 
Experimental Procedures 
Human Brain Tissue and Antibodies 
Autopsy material from AD individuals (n = 32) was obtained from the 
Huddinge Brain Bank, Huddinge Hospital, Sweden. AD diagnosis was 
confirmed according to standard protocols (McKhann et al., 1984). 
The AD cases had an average age of 78 years (range = 57-94 years). 
The control cases (n = 4) were obtained from the Department of Foren- 
sic Medicine, Karolinska Institute, Stockholm, Sweden. Neither gross 
pathological examination nor clinical records revealed any sign of de- 
mentia or other neurological disorders, and the average age of the 
control cases was 75 years (range = 60-86 years). Occipital cortex 
(IO-40 g) from both AD and control cases was removed at autopsy 
and stored at -70°C until further use. Occipital cortex was used for 
reasons of availability. ApoE genotypes were determined from brain 
tissue as described (Wenham et al., 1991). The antibodies used in 
this study were either from commercial sources or have, with one 
exception, been described previously. The monoclonal antibodies 
used were 6ElO (Kim et al., 1990), 4G8 (Kim et al., 1988), 2El (Boeh- 
rmger), 1048(Chemicon), lD7and 3Hl (Milneetal.. 1981; Weisgraber 
et al., 1983), 22Cll (Boehringer), Alz 90 (Boehringer), 56-l (Wunder- 
lich et al., 1992), tau-l (Boehringer), and AT-8 (Innogenetics). The 
following antisera were also used: G504 (see below), anti-AD (Boeh- 
ringer), 369A (Buxbaum et al., 1990), anti-ACT (Calbiochem), anti- 
ubiquitin (Boehringer), and anti-TTR (Sigma). The general specificities 
of these antibodies are given in Table 1. Polyclonal antiserum G504. 
a gift from Dr. Toshiharu Suzuki, Rockefeller University, was raised 
in rabbits against AP(l-40) and purified by affinity chromatography 
using Ae(l-40) Immobilized on a Hi-Trap NHS column (Pharmacia). 
Amyloid Extraction 
Brain tissue was extracted as described (Ntislund et al., 1994). Bnefly, 
repeated extraction of the tissue in a buffer containing 1% SDS, 0.1 
mM phenylmethylsulfonyl fluoride, 150 mM NaCI, and 50 mM Tns- 
HCI (pH 7.4) yielded a SDS-insoluble pellet that In turn was extracted 
with 1 ,I ,1,3,3.3-hexafluoro-2.propanol (HFIP). After removal of debris 
and delipidation, the HFIP extract wasdried under a stream of nitrogen 
Protein determination was performed using the bicinchonlnic acid 
assay (Pierce). Samples were initially dissolved in 9 M  urea, 50 mM 
Tris-HCI (pH 7.4), boiled for 5 min, and diluted to 3 M  urea with water 
prior to protein determination. 
SDS-PAGE and lmmunoblotting 
Samples were dissolved in 9 M  urea and sonicated (Branson Sonifier 
250) before addition of 3 x SDS-PAGE sample buffer. The samples 
were boiled and resolved on a 54/o-18% Tris-Tricine gradient gel sys- 
tem. After electrophoresis, the proteins were electroblotted onto nitro- 
cellulose membranes (0.2 urn; Schleicher & Schuell) or polyvinylidene 
difluoride membranes (0.45 pm; Millipore). Membranes were probed 
with monoclonal antibodies or antisera for 3-12 hr at room tempera- 
ture, and antibody binding was detected by adding horseradish perox,- 
dase-linked sheep anti-mouse, donkey anti-rabbit (both supplied by 
Amersham), or rabbit anti-goat (Sigma) immunoglobulin, depending 
on the host animal providing the primary antibody. The blots were 
visualized usmg the enhanced chemiluminescence system (Amer- 
sham) according to the instructions of the manufacturer. Quantitatlon 
of the blots was performed using a Bio-Rad Model GS-670 densitome- 
ter and the accompanying Molecular Analyst software. 
Purification of the Afl-apoE Complexes 
The dry HFIP extracts were dissolved in 70% (v/v) distilled formic acid, 
centrifuged at 10,000 x g for 2 min (to remove insoluble material), 
and purified by gel filtration on a 1 x 30 cm Superose 12 column 
(Pharmacia) developed with 70% formic acid at a flow rate of 200 pII 
min (Roher et al., 1993). Absorbance was monitored at 280 nm, and 
aliquots of the collected fractions were dried by vacuum centrifugation 
after addition of SDS (0.1% final concentration). The dried aiiquots 
were subjected to immunoblotting, the fractions containing the AD- 
apoE complexes and noncomplexed AD were pooled separately, and 
the solvent was evaporated. The Afl-apoE complexes were redis- 
solved in 70% formic acid and further purified by RPLC using a 0.46 
x 15 cm Vydac 214 TP C4 column developed over 30 min with a 
linear gradient of O%-80% buffer B, where buffer A was 60% formic 
acid in 0.1% TFA and buffer B was buffer A containing 40% ACN 
(Heukeshoven and Dernick, 1985). Flow rate was set at 500 jdlmin, 
and absorbance was monitored at 280 nm. Aliquots of the collected 
fractions were evaporated after addition of SDS (0.1% final concentra- 
tion) and analyzed by immunoblotting. Fractions containing Ap-apoE 
complexes were pooled, evaporated, and used for immunological 
characterization, digestion, dissociationstudies, and lightandelectron 
microscopy (see below). 
Enzymatic Digestion and Microsequencing 
of the Ap-apoE Complexes 
The partially purified AD-apoE complexes were alkylated with Cvinyl- 
pyridine according to standard procedures. Desalting of the alkylated 
proteins was performed on a 0.32 x 10 cm FastDesalting column 
(Pharmacia) developed with 20% ACN, 0.1% TFA at a flow rate of 
100 pllmin, while monitoring absorbance at 254 and 280 nm. The 
void fraction was evaporated to dryness, and the alkylated AD-apoE 
complexes were resuspended in 10 pl of 9 M  urea. After dilution to 1 
M  urea with 0.1 M  ammonium bicarbonate buffer (pH 7.8), digestions 
were performed with endoproteinase Lys-C (Boehringer) or modified 
trypsin(Promega) for 18 hrat 37OCat anenzyme:substrate ratio(mass/ 
mass) of approximately 1:20. The incubations were terminated by the 
addition of TFA (0.1% final concentration). After evaporation, the di- 
gests were resuspended in 0.1% TFA and centrifuged at 10,000 x g 
for 2 min. The resulting supernatant and pellet were treated separately. 
The peptides in the supernatant were separated by RPLC using a 
Pharmacia SMART system equipped with a 0.21 x 10 cm C2-Cl8 
mRPC column (Pharmacia) developed over 40 min with a linear gradi- 
ent of O%-50% ACN in 0.1% TFA at a flow rate of 100 pllmin. The 
pellet was dissolved in 70% formic acid and diluted with 0.1% TFA 
to a final formic acid concentration of 10% before separation on a 
0.21 x 15 cm Vydac 214 TP C4 column developed with the same 
solvent system as for the supernatant peptides. N-terminal sequencing 
of the peptide fragments was performed on an Applied Biosystems 
Model 477 A gas-phase microsequencer using procedures according 
to the manufacturer. 
Dissociation Studies of the Ap-apoE Complexes 
One milliliter of each of the agents listed below was added to the 
purified AD-apoE complexes. The complexes were incubated in poly- 
propylene tubes with each agent for 12-48 hr. The samples were 
then diluted with water and dialyzed, using benzoylated dialysis tubing 
(Sigma), against 0.1 M  ammonium bicarbonate (pH 7.8), before evapo- 
ration and analysis by immunoblotting. The agents used were SDS 
(lo%), urea (10 M), guanidine-HCI (6 M), phenol (90%), HFIP (1 OO%), 
ACN (lOO%), NH,OH (25%). NaOH (1 M), TFA (30%), and formic acid 
(70%100%). 
Light and Electron Microscopy 
Purified A@apoE complexes were suspended in 50% ethanol con- 
taining 1% Congo red (Bush et al., 1994). The suspension was 
smeared onto glass slides and viewed under polarized light. For elec- 
tron microscopy, the AD-apoE complexes and noncomplexed AD puri- 
fied from AD brain (see Figure 2A, fraction 9) were dissolved in HFIP 
before dilution in Tris-buffered saline (TBS) to a final concentration of 
5% HFIP. The samples were incubated in TBS (pH 7.4) at 37OC for 
1 hr and pelleted by centrifugation at 20,000 x g for 20 min using a 
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Beckman TLA 45 rotor. The pellets were washed twice with water and 
resuspended in a final volume of 50 aI of water. Following sonication 
(Branson Sonifier 250) 5 ul aliquots were placed on copper grids 
covered by a carbon-stabilized Formvar film, and 5 ul of freshly pre- 
pared 2% uranyl acetate in water was added. After l-2 min, excess 
fluid was removed with a filter paper and the grids were air-dried. The 
specimens were examined and photographed in a JEOL EM 1OOCX 
at 60 kV. For immunogold staining, A6-apoE complexes were ad- 
sorbed to nickel grids covered by a carbon-stabilized Formvar film and 
air-dried. After washing in TBS for 2 min, nonspecific binding was 
blocked by incubation in TBS with 3% bovine serum albumin (BSA) 
for 30 min. The grids were then placed on a droplet of either the 
apoE-specific antibody 2E1 (1:50) or normal mouse IgG for 60 min 
(both diluted in TBS, 0.1% BSA), passed over six droplets of washing 
solution for 2 min each (TBS., 0.1% BSA), placed on a droplet of anti- 
mouse IgG conjugated to 10 nm colloidal gold particles for 30 min 
(Sigma; diluted 1:20 in TBS, 0.1% BSA). and passed over another six 
droplets of washing solution. The grids were fixed in 2% glutaralde- 
hyde in 0.1 M  sodium cacodylate-HCI buffer (pH 7.3) for 5 min, washed 
under a jet of water from a Pasteur pipette for 15-20 s, and air-dried. 
Before the final examination in the electron microscope, the specimens 
were negatively stained with 2% uranyl acetate in water. 
Generation of Ap-apoE Complexes In Vitro 
A6(1-40) and A6(1-42) were dissolved at 200 uM in 20 mM HEPES, 
150 mM NaCI, 0.05% CHAPS (pH 6.90) by sonication. To create reduc- 
ing conditions, 10 mM DTT was included in the buffer. Recombinant 
apoE (PanVeraCorp., Madison, Wisconsin) at 1 mglml in 0.7 M  ammo- 
nium bicarbonate was added to a final concentration of 50 ug/ml (1.47 
KM), which adjusted the pH of the incubation solution to 7.4. The 
incubation volume was 50 ul, and the amount of each reactant was 
corroborated by amino acid analysis (apoE) and RPLC (A6). After 4 
days of incubation at 37% in a shaking water bath, the A6-apoE 
complexes were pelleted by centrifugation at 20,000 x g for 20 min 
in a Beckman TLA 45 rotor (4%). The pellets were resuspended in 
HFIP for 30 min at room temperature and dried, before analysis by 
immunoblotting. To remove noncomplexed apoE and A5 before elec- 
tron microscopy, the HFIP-treated and dried pellets were dissolved in 
70% formic acid. The AD-apoE complexes were purified by gel filtra- 
tion in 70% formic acid on a 0.32 x 30 cm Superose 12 column 
(Pharmacia) using the SMART system. The fractions containing the 
A6-apoE complexes, as determined by immunoblotting, were pooled, 
dried, and preparedforelectron microscopyasdescribedforthe invivo 
samples. Samples in which A6 was incubated alone were subjected to 
thesamepurificationprocedure, andthesamefractionswerecollected 
as above. 
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